Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Efficacy of CRISPR Base Editing Therapies in Preclinical Models of Genetic Blood Disorders

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Efficacy of CRISPR Base Editing Therapies in Preclinical Models of Genetic Blood Disorders

Preclinical Efficacy Models for CRISPR Base Editing in Hematological Disorders

CELL & GENE | RNA | BIOLOGICS

Assessing the preclinical efficacy of CRISPR base editing therapies for genetic blood disorders requires specialized in vivo models and advanced bioanalytical assays. The primary challenges involve optimizing delivery to target hematopoietic cells and accurately quantifying the functional consequences of the edit. Franklin Biolabs provides robust, GxP-compliant pharmacology studies that integrate advanced non-viral delivery system evaluation with comprehensive next-generation sequencing (NGS) and functional readouts to generate a complete data package for regulatory submission.

    What are the primary challenges in assessing preclinical efficacy for base editing therapies in blood disorders?

    A: Key hurdles include achieving sufficient delivery efficiency to hematopoietic stem cells, precisely quantifying on-target versus off-target editing events across the genome, and demonstrating the long-term durability and safety of the therapeutic correction in a relevant biological system.

    How do you model human hematological disorders for these studies?

    A: We utilize well-characterized in vivo models that accurately recapitulate the specific genetic mutations and disease phenotypes. This allows for a robust evaluation of therapeutic correction and provides translational data on both efficacy and potential safety liabilities.

    What bioanalytical methods are used to quantify editing efficiency?

    A: Our core platform employs next-generation sequencing (NGS) for definitive quantification of on-target editing frequencies and unbiased, genome-wide off-target analysis. This is complemented by functional assays, such as flow cytometry or protein analysis, to measure biological restoration.

    How does Franklin Biolabs address the delivery challenge for CRISPR base editors?

    A: We have extensive experience characterizing lipid nanoparticle (LNP) formulations and other non-viral vectors. We focus on optimizing constructs for targeted delivery and improved endosomal escape, a known barrier for large ribonucleoprotein complexes as highlighted in recent literature.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Defining Efficacy Beyond On-Target Editing

Evaluating a base editing therapeutic requires a multi-faceted approach. While the percentage of on-target edits provides a primary metric, a comprehensive efficacy assessment also quantifies the degree of functional restoration and its durability over time. Our study designs incorporate long-term observation points to assess the stability of the genetic correction and its downstream biological impact. This approach provides a clear line of sight from molecular correction to phenotypic rescue.

Key efficacy endpoints include:

  • Quantification of on-target editing efficiency in target cell populations.

  • Measurement of functional protein restoration or target gene expression changes.

  • Assessment of phenotypic correction in disease-relevant models.

  • Longitudinal analysis to confirm the durability of the therapeutic effect.

Overcoming the Delivery Barrier with Advanced Formulations

The in vivo delivery of large CRISPR-Cas9 ribonucleoprotein (RNP) complexes remains a significant technical challenge. Non-viral vectors, particularly LNPs, are a primary focus for clinical translation. As recent research demonstrates [PMID: 39856035], innovations in lipid chemistry to improve endosomal escape are pivotal for enhancing the efficiency of both mRNA and RNP delivery. Our pharmacology programs are designed to evaluate these advanced formulations, providing definitive data on how novel delivery systems perform in a whole-animal context and ensuring your therapeutic payload reaches its intended target.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Animal Welfare and GxP-Compliant Study Design

Our programs are fully accredited by AAALAC International and operate in compliance with USDA regulations within our >100,000 sq ft GxP-compliant facility.

Integrated Bioanalysis for a Complete IND Picture

A successful regulatory submission depends on a cohesive data package. We integrate pharmacology studies with comprehensive bioanalytical support, including NGS-based on-target and off-target analysis, functional assays, and non-target tissue biodistribution studies. This integrated strategy provides the clear, defensible data required to meet regulatory expectations. This rigorous approach has supported an 18-24 month average IND timeline for our partners and a 100% IND success rate since 2019. Franklin Biolabs as a brand was launched in 2024, building upon this established record of scientific excellence.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities